List view / Grid view
24 March 2015 | By Victoria White
Novo Nordisk has announced that the European Commission has granted marketing authorisation for Saxenda ® (liraglutide 3 mg) for the treatment of obesity...
6 February 2015 | By Janssen EMEA
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…
21 January 2015 | By Aurora
A once daily injection has been approved for adults with type 2 diabetes and moderate renal impairment (stage 3 chronic kidney disease) in the UK...
19 January 2015 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014. Nintedanib* will be marketed in the EU under the brand name OFEV®...
27 November 2014 | By European Alcohol Policy Alliance
Today over 300 representatives from Health Ministries, the European Institutions, public health experts and concerned stakeholders have gathered in Brussels to call on the European Commission President Jean-Claude Juncker and his team to take actions to prevent and reduce the burden of alcohol on European societies...
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
8 September 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate...
24 July 2014 | By Biogen Idec
Biogen Idec announced that the European Commission has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a)...
23 May 2014 | By Boehringer Ingelheim
The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company...
14 May 2014 | By The European Medicines Agency
The European Commission and the US Department of Health and Human Services have published a progress report of the Transatlantic Taskforce on Antimicrobial Resistance...
3 February 2014 | By Biogen Idec
Biogen Idec to begin launching TECFIDERA in initial EU Countries in the coming weeks...
14 March 2013 | By Pegasus
The EC has approved expanded options for pre-treatment prior to use of QUTENZA...
20 November 2012 | By Bristol-Myers Squibb Company
The EC has approved ELIQUIS®...
4 September 2012 | By F T I Consulting
The European Commission has granted European market authorization for the medicinal product teduglutide...
